Skip to content

Xencor XNCR Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
XOMA Corporation logo
XOMA CorporationXOMA
Zymeworks logo
ZymeworksZYME

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's proceeds from exercises of stock options and other stock issuances?
Xencor (XNCR) reported proceeds from exercises of stock options and other stock issuances of $950K in Q1 2026.
How has Xencor's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Xencor's proceeds from exercises of stock options and other stock issuances decreased by 68.1% year-over-year, from $2.97M to $950K.
What is the long-term trend for Xencor's proceeds from exercises of stock options and other stock issuances?
Over 3 years (2021 to 2024), Xencor's proceeds from exercises of stock options and other stock issuances has grown at a -19.9% compound annual growth rate (CAGR), from $12.28M to $6.31M.